Authors
Latest:
Future Perspectives: Treating Multiple Myeloma With Novel RegimensAn overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Latest:
Exploring the Future of ctDNA and Novel Treatment StrategiesPanelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.
Latest:
Kim A. Reiss Binder, MD, Reviews PARP Plus Immunotherapy in Platinum-Sensitive Advanced Pancreatic AdenocarcinomaKim A. Reiss Binder, MD, spoke about the use of niraparib plus either nivolumab or ipilimumab for patients with platinum-sensitive advanced pancreatic adenocarcinoma.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
CAR-NKT cells: More of a Goldilocks or a Kangaroo?The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
Latest:
Elacestrant Combos Can Open New Pathways in ESR1 Breast Cancer TreatmentMultiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said.
Latest:
Unmet Needs and Future Directions in Care in Multiple MyelomaClosing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.
Latest:
Current Frontline Treatment of Multiple MyelomaSarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Adverse Event Considerations in DLBCLMedical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Non-Clear Cell RCC: Key Learnings and Future Research DirectionsThe panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.
Latest:
CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and PrognosisPanelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Unmet Needs and Looking Ahead in Follicular LymphomaSameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.
Latest:
The Future of BRAF-Mutant mCRC ManagementChristina Wu, MB, BCh, MD, closes the program by expressing the necessity of enrolling patients with BRAF-mutant metastatic colorectal cancer in clinical trials, highlighting a second-line study led by the Southwest Oncology Group, new BRAF inhibitors, early phase studies at the Mayo Clinic, and an exciting study in the adjuvant setting.
Latest:
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer SurvivorshipThe lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.
Latest:
Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to ConceiveABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.
Latest:
Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in CareBest treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Latest:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsRead about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
